Clinical Trial Results:
A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis
Summary
|
|
EudraCT number |
2009-015845-21 |
Trial protocol |
GB DE CZ FI BE SE PT GR ES |
Global completion date |
31 Jan 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Jul 2016
|
First version publication date |
22 May 2015
|
Other versions |
|
Summary report(s) |
WA19924 (CTg receipt |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.